LPCN: Net loss widened in Q2 2026, but cash position improved and TLANDO royalties increased
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw a net loss increase to $2.6M, with higher R&D and G&A expenses, but cash reserves rose to $23.3M. LPCN 1154's Phase 3 trial missed its primary endpoint, though post hoc analysis excluding an outlier site showed promising results. TLANDO royalty revenue grew year-over-year.Original document: Lipocine Inc. [LPCN] SEC 8-K Current Report — Aug. 4 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw a net loss increase to $2.6M, with higher R&D and G&A expenses, but cash reserves rose to $23.3M. LPCN 1154's Phase 3 trial missed its primary endpoint, though post hoc analysis excluding an outlier site showed promising results. TLANDO royalty revenue grew year-over-year.
Original document: Lipocine Inc. [LPCN] SEC 8-K Current Report — Aug. 4 2026